Literature DB >> 16705520

[Long-term follow-up and angiographic findings in serpiginous choroiditis].

B M Stoffelns1.   

Abstract

BACKGROUND: Long-term follow-up and angiographic findings of serpiginous choroiditis, a chronic disease with recurrences of unknown origin, are reported. PATIENTS AND METHODS: A retrospective analysis of the data of 4 patients with serpiginous choroidopathy, who were treated in the eye clinic of Mainz in the past 10-18 years was made. Progression of disease was documented by photography, as well as fluorescein and indocyanine green angiography. Patients with acute lesions were treated with steroids per os for some weeks.
RESULTS: All 8 eyes developed 2-7 recurrences with progression of the chorioretinal scars. In cases of macular involvement the functional results were worse. No choroidal neovascularizations were seen. During follow-up 3/8 eyes became blind, 4/8 eyes retained reading vision. Indocyanine green angiography usually demonstrated many more lesions than those seen with fluorescein. In 3 cases acute choroidal lesions were detected only with indocyanine green angiography whereas no sign of inflammation was demonstrated by fluorescein angiography.
CONCLUSION: The functional prognosis of serpiginous choroiditis is bad because all eyes developed at least 2 recurrences during follow-up. Use of indocyanine green angiography may help to better describe the full extent of the disease, even before it is seen with fluorescein angiography. It can help the observer to determine the precise clinical progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705520     DOI: 10.1055/s-2006-926575

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  1 in total

1.  Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis).

Authors:  Ilknur Tugal-Tutkun; Carl P Herbort; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2008-09-16       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.